Published in Transplantation on April 01, 1988
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation (1974) 10.91
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med (1980) 9.64
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med (2001) 5.59
Reducing morbidity from chest drains. BMJ (1997) 4.35
Bone-marrow transplantation (second of two parts). N Engl J Med (1975) 4.11
Bone marrow transplantation for sickle cell disease. N Engl J Med (1996) 4.02
Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med (1979) 3.59
Bone-marrow transplantation (first of two parts). N Engl J Med (1975) 3.33
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med (1986) 3.22
Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood (1981) 3.03
Use of the flagellar H7 gene as a target in multiplex PCR assays and improved specificity in identification of enterohemorrhagic Escherichia coli strains. J Clin Microbiol (1997) 2.98
Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc (1974) 2.95
The canine major histocompatibility complex. Supertypic specificities defined by the primed lymphocyte test (PLT). Immunogenetics (1984) 2.72
Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med (1981) 2.61
Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med (1989) 2.42
One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood (1977) 2.36
Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood (1996) 2.30
Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med (1985) 2.30
Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood (1976) 2.29
Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med (1988) 2.19
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood (1992) 2.14
Retroviral transfer of genes into canine hemopoietic progenitor cells in culture: a model for human gene therapy. Proc Natl Acad Sci U S A (1986) 2.14
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant (2001) 2.10
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 2.04
Communication skills in veterinary education. J Am Vet Med Assoc (1994) 2.01
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia (2006) 1.92
Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol (1990) 1.91
Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med (1983) 1.89
A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood (1979) 1.83
Technique for human marrow grafting. Blood (1970) 1.83
Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood (1997) 1.80
Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood (1995) 1.79
Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood (1996) 1.77
Allogeneic marrow grafting for treatment of aplastic anemia. Blood (1974) 1.76
The prevalence of verotoxins, Escherichia coli O157:H7, and Salmonella in the feces and rumen of cattle at processing. Can Vet J (1999) 1.74
Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol (1988) 1.72
Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation (1996) 1.72
Marrow transplantation for thalassaemia. Lancet (1982) 1.71
Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood (2001) 1.66
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood (1997) 1.64
Long-term outcome after marrow transplantation for severe aplastic anemia. Blood (1998) 1.63
Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann Intern Med (1997) 1.59
Marrow toxicity of fractionated vs. single dose total body irradiation is identical in a canine model. Int J Radiat Oncol Biol Phys (1993) 1.57
Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Engl J Med (1981) 1.56
DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing. Tissue Antigens (1998) 1.51
Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol (1995) 1.50
Interstitial pneumonia and cytomegalovirus infection as complications of human marrow transplantation. Transplantation (1973) 1.48
Multiple controls of oxidative metabolism in living tissues as studied by phosphorus magnetic resonance. Proc Natl Acad Sci U S A (1986) 1.46
Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med (1983) 1.44
Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med (1979) 1.44
Lactate and potassium fluxes from human skeletal muscle during and after intense, dynamic, knee extensor exercise. Acta Physiol Scand (1990) 1.42
Pharmacologic, toxicologic, and marrow transplantation studies in dogs given succinyl acetone. Transplantation (1992) 1.41
Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation (2001) 1.41
T-cell subpopulations identified by monoclonal antibodies after human marrow transplantation. I. Helper-inducer and cytotoxic-suppressor subsets. Blood (1982) 1.39
High resolution genotyping of Bacillus anthracis outbreak strains using four highly mutable single nucleotide repeat markers. Lett Appl Microbiol (2008) 1.39
Aplastic anaemia treated by marrow transplantation. Lancet (1972) 1.39
Aplastic anemia (first of two parts): pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med (1982) 1.38
Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation (1970) 1.37
The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood (1993) 1.36
Ultrastructure of rosette-forming cells in the mouse during the antibody response. J Immunol (1969) 1.35
A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood (1991) 1.35
Allogeneic bone-marrow transplantation. Immunol Rev (1983) 1.34
Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol (1989) 1.33
Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood (1999) 1.31
T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant (1995) 1.31
Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. N Engl J Med (1977) 1.31
Graft-versus-host disease: pathophysiological and clinical aspects. Annu Rev Med (1984) 1.29
Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant (2006) 1.29
Reducing psychiatric stigma and discrimination--evaluating an educational intervention with the police force in England. Soc Psychiatry Psychiatr Epidemiol (2003) 1.28
Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol (1997) 1.27
Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood (1996) 1.27
Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood (1996) 1.26
Rapidly progressive air-flow obstruction in marrow transplant recipients. Possible association between obliterative bronchiolitis and chronic graft-versus-host disease. Am Rev Respir Dis (1984) 1.26
Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood (1996) 1.25
Cytotoxic typing antisera for marrow grafting in littermate dogs. Transplantation (1968) 1.25
Use of (CA)n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation (1994) 1.25
Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. Blood (2001) 1.24
Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood (1997) 1.23
Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia. Br J Haematol (1983) 1.23
Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood (1988) 1.23
Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics (1992) 1.22
Bone-marrow transplantation for hematologic neoplasia in 16 patients with identical twins. N Engl J Med (1974) 1.22
Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood (2000) 1.22
Chronic cutaneous graft-versus-host disease in man. Am J Pathol (1978) 1.21
Analysis of late infections in 89 long-term survivors of bone marrow transplantation. Blood (1979) 1.21
Lactate and H+ effluxes from human skeletal muscles during intense, dynamic exercise. J Physiol (1993) 1.20